Skip to main content
TheraSonic logo

TheraSonic

Paris, FranceSee on the map

  • Focused ultrasound
  • Seed

TheraSonic develops medical devices that use non-invasive focused ultrasound to enable drug delivery to the brain. Its technology aims to temporarily and locally increase the permeability of the blood-brain barrier, supporting potential treatments for brain cancers and neurological diseases.

Raised
$1.1M
May 2024
Seed
Investors
2

reccy insights

Recent highlights

TheraSonic’s disclosed milestones include its 2023 spinoff and a Seed round dated May 14, 2024, with Gustave Roussy and M2care listed as lead investors. A further funding entry dated Jul 16, 2026 is labeled “Funding - Pending” and names no identifiable lead investor. The company’s stated focus is non-invasive focused ultrasound for localized, temporary blood-brain barrier permeability, with the aim of supporting drug delivery to the brain. Its described areas of interest include brain cancer and neurological diseases. The available funding figures also require caution: the overall funding estimate is $1.08 million, while a separate equity entry gives an amount in euros without a date. That euro figure is not included in the USD-denominated round amounts here. The milestones indicate financing activity, but they do not establish clinical outcomes, commercialization progress, or the status of any product.

Written by reccy's AI from company sites, press and funding records · updated Nov 2026

What makes TheraSonic distinct

  1. 01Uses focused ultrasound to address the blood-brain barrier, which can limit medicines from reaching targets in the brain.
  2. 02Combines focused ultrasound with microbubbles to enable localized, temporary blood-brain barrier permeability.
  3. 03Targets potential applications in brain cancer and neurological diseases, including neurodegenerative conditions.
  4. 04Emphasizes patient-focused work and collaboration.

Technology & products

  • Focused ultrasound (FUS) for targeted blood-brain barrier disruption.
  • Focused ultrasound combined with microbubbles to temporarily increase blood-brain barrier permeability.

Research roots1

Labs and research groups this company came from or works with.

  • Université de StrasbourgStrasbourg, France · No page yet
    Named on record
Academic data: Carter Sciences

Recent updates1

  • Jul 22, 2025Team change

    Therasonic nomme Geraldine Le Duc présidente de son comité stratégique

    therasonic.fr

Funding

$1.1M disclosed
  • Funding - PendingJul 2026
  • SeedMay 2024
    Gustave Roussy, M2care
  • Spinoff / SpinoutJan 2023
2 investors

Investors4

On reccy
Also backed by
  • Gustave Roussy
  • CEA Investissement
  • Gustave Roussy Transfert

Similar companies

About TheraSonic

Focus areas
Medical devices, focused ultrasound, drug delivery, blood-brain barrier, neurotechnology, neurology, brain cancer, therapeutics
Headquarters
Paris, France